E-DRUG: 3 Reasons: Why should we invest in national regulatory authorities
---------------------------------------------------------------------------
Dear E-Drug Listers,
To champion the call for increased investment in national regulatory
authorities (NRAs) for greater access to safe, effective, and
quality-assured medicines, USAID MTaPS experts, Gloria Twesigye, Tamara
Hafner, and Javier Guzman have recently co-authored a commentary, published
in the Journal of Pharmaceutical Policy and Practice. While the benefits of
functional NRAs are diffused and often unseen, weak NRAs have serious,
negative impacts.
The authors offer three arguments for greater investment
in regulatory systems strengthening, focused on safeguarding public health;
increasing health system's efficiency; and bolstering local pharmaceutical
manufacturing and trade.
Check out their arguments in the article: 'Making the investment case for
national regulatory authorities' published in Journal of Pharmaceutical
Policy and Practice, January 21, 2021:
https://joppp.biomedcentral.com/articles/10.1186/s40545-021-00299-7
Best wishes,
Rajita
Rajita Majumdar
Strategic Communications Lead
USAID Medicines, Technologies, and Pharmaceutical Services (MTaPS) Program
E-mail: rmajumdar@mtapsprogram.org